5.01.522 Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
ثبت نشده
چکیده
The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1): ambrisentan (LETAIRIS®) oral; bosentan (TRACLEER®) oral; epoprostenol sodium (e.g., FLOLAN®) continuous IV infusion; Iloprost (VENTAVIS®) Inhalation via nebulizer; macitentan (OPSUMIT®) oral; riociguat (ADEMPAS®) oral; sildenafil citrate (e.g., REVATIO®) oral; tadalafil (ADCIRCA®) oral; treprostinil sodium (REMODULIN®) Continuous SC infusion, IV infusion or (TYVASO®) inhalation via nebulizer, or Orenitram® oral; and vardenafil (LEVITRA®) oral.
منابع مشابه
5.01.522 Advanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
The following therapies may be considered medically necessary for the treatment of pulmonary arterial hypertension (PAH/ WHO Group 1): ambrisentan (LETAIRIS®) oral; bosentan (TRACLEER®) oral; epoprostenol sodium (e.g., FLOLAN®) continuous IV infusion; Iloprost (VENTAVIS®) Inhalation via nebulizer; macitentan (OPSUMIT®) oral; riociguat (ADEMPAS®) oral; sildenafil citrate (e.g., REV...
متن کاملAdvanced Therapies for Pharmacological Treatment of Pulmonary Arterial Hypertension
Policy Blue Cross and Blue Shield of Kansas City will provide coverage for the pharmacologic treatment of pulmonary arterial hypertension (PAH) with prostacyclin analogues, endothelin receptor antagonists, or phosphodiesterase type 5 (PDE5) inhibitors when it is determined to be medically necessary because the following criteria are met. Conventional pharmacologic therapies are considered in al...
متن کاملEisenmenger syndrome: not always inoperable.
Recently, advanced therapies for pulmonary arterial hypertension have become available, and have been effective in reducing pulmonary vascular resistance and symptoms in patients with Eisenmenger syndrome, previously thought to be inoperable. This review summarizes the current knowledge on the pathophysiology and treatment of Eisenmenger syndrome. The recent introduction of targeted therapies ...
متن کاملThe pharmacological treatment of pulmonary arterial hypertension.
Pulmonary arterial hypertension (PAH) is a life-threatening and progressive disease of various origins characterized by pulmonary vascular remodeling that leads to increased pulmonary vascular resistance and pulmonary arterial pressure, most often resulting in right-sided heart failure. The most common symptom at presentation is breathlessness, with impaired exercise capacity as a hallmark of t...
متن کاملبررسی اثر تادالافیل خوراکی در کاهش پرفشاری شریان ریوی در کودکان و نوجوانان 5 ماهه تا 15 ساله
Introduction: Pulmonary arterial hypertension in children has consequences such as right ventricular failure and even death. Recently, the use of phosphodiesterase 5 inhibitors has been taken into account in the treatment of pulmonary hypertension, among which tadalafil is more acceptable by parents and patients due to its single dose per day compared to sildenafil which should be taken 4 times...
متن کامل